Rockefeller Capital Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.25M Buy
5,554
+1,428
+35% +$356K ﹤0.01% 1511
2025
Q4
$994K Buy
4,126
+1,855
+82% +$474K ﹤0.01% 1561
2025
Q3
$622K Buy
+2,271
New +$620K ﹤0.01% 1667
2024
Q4
Sell
-38,625
Closed -$9.42M 1718
2024
Q3
$9.42M Sell
38,625
-338
-0.9% -$75.5K 0.03% 562
2024
Q2
$7.46M Sell
38,963
-22,152
-36% -$4.49M 0.02% 588
2024
Q1
$12.1M Buy
61,115
+2,666
+5% +$489K 0.04% 446
2023
Q4
$10.1M Sell
58,449
-7,295
-11% -$1.12M 0.03% 459
2023
Q3
$9.72M Sell
65,744
-36,928
-36% -$6.68M 0.04% 425
2023
Q2
$22.4M Sell
102,672
-33,417
-25% -$7.45M 0.09% 238
2023
Q1
$29.8M Buy
136,089
+124,311
+1,055% +$27M 0.13% 181
2022
Q4
$2.45M Sell
11,778
-133,846
-92% -$29.4M 0.01% 685
2022
Q3
$31.8M Sell
145,624
-1,374
-0.9% -$313K 0.16% 137
2022
Q2
$30.8M Sell
146,998
-69,617
-32% -$14.8M 0.16% 142
2022
Q1
$52.5M Sell
216,615
-32,149
-13% -$7.78M 0.25% 93
2021
Q4
$64.8M Buy
248,764
+974
+0.4% +$253K 0.3% 75
2021
Q3
$65.3M Sell
247,790
-17,771
-7% -$4.86M 0.34% 66
2021
Q2
$65.5M Sell
265,561
-6,214
-2% -$1.31M 0.37% 56
2021
Q1
$52.7M Sell
271,775
-1,284
-0.5% -$257K 0.36% 63
2020
Q4
$58M Sell
273,059
-6,629
-2% -$1.32M 0.44% 46
2020
Q3
$47.9M Buy
279,688
+1,812
+0.7% +$335K 0.45% 47
2020
Q2
$53.4M Buy
277,876
+3,916
+1% +$641K 0.56% 36
2020
Q1
$40.4M Buy
273,960
+93,925
+52% +$15M 0.53% 36
2019
Q4
$27.9M Buy
180,035
+475
+0.3% +$68.5K 0.35% 62
2019
Q3
$24.3M Sell
179,560
-2,878
-2% -$377K 0.33% 73
2019
Q2
$22.3M Sell
182,438
-3,517
-2% -$390K 0.31% 80
2019
Q1
$19.3M Buy
185,955
+2,066
+1% +$213K 0.28% 84
2018
Q4
$20.9M Sell
183,889
-3,760
-2% -$403K 0.37% 68
2018
Q3
$21.6M Sell
187,649
-4,891
-3% -$536K 0.33% 74
2018
Q2
$19.9M Sell
192,540
-5,059
-3% -$512K 0.32% 75
2018
Q1
$19.5M Buy
+197,599
New +$18.7M 0.32% 78

Other funds holding RMD

Rockefeller Capital Management's RMD Position: Q1 2026 in Review

Rockefeller Capital Management increased its ResMed (RMD) stake by 35% in Q1 2026, buying an estimated $356K and bringing the position to 5,554 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

Rockefeller Capital Management first reported a position in RMD in Q1 2018 and has held it in 30 quarters since. The position peaked at $65.5M in Q2 2021. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Rockefeller Capital Management held 5,554 shares of ResMed worth $1.25M as of Q1 2026.
  • Rockefeller Capital Management bought 1,428 ResMed shares in Q1 2026, an estimated $356K.
  • ResMed made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1511 holding.
  • Rockefeller Capital Management first reported a position in ResMed in Q1 2018 and has held it in 30 quarters since.
  • Rockefeller Capital Management's ResMed position peaked at $65.5M in Q2 2021.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.